エビリファイ散１％
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB01238 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 54 |
| 日本商品名（例） | アリピプラゾール内用液分包１２ｍｇ「ニプロ」 ０．１％１２ｍＬ, アリピプラゾール内用液分包１２ｍｇ「明治」 ０．１％１２ｍＬ, アリピプラゾール内用液分包３ｍｇ「ニプロ」 ０．１％３ｍＬ |
承認適応症（KEGG）
統合失調症、双極性障害における躁症状、うつ病・うつ状態
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | manic bipolar affective disorder | 99% | DL |
| 2 | autism susceptibility 1 | 99% | DL |
| 3 | autism spectrum disorder | 99% | DL |
| 4 | bipolar disorder | 99% | DL |
| 5 | major affective disorder | 99% | DL |
| 6 | gaze palsy, familial horizontal, with progressive scoliosis | 99% | DL |
| 7 | schizophrenia | 99% | DL |
| 8 | asperger syndrome, susceptibility to | 99% | DL |
| 9 | Phelan-McDermid syndrome | 99% | DL |
| 10 | amelocerebrohypohidrotic syndrome | 99% | DL |
| 11 | distal 17p13.3 microdeletion syndrome | 99% | DL |
| 12 | trichotillomania | 99% | DL |
| 13 | Malan overgrowth syndrome | 99% | DL |
| 14 | retinal dystrophy with or without extraocular anomalies | 99% | DL |
| 15 | hydranencephaly (disease) | 99% | DL |
| 16 | congenital disorder of glycosylation with defective fucosylation | 99% | DL |
| 17 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99% | DL |
| 18 | myopia X-linked | 99% | DL |
| 19 | syndromic myopia | 98% | DL |
| 20 | myopia 26, X-linked, female-limited | 98% | DL |
| 21 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | 98% | DL |
| 22 | intellectual disability | 98% | DL |
| 23 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 98% | DL |
| 24 | autism, susceptibility to | 98% | DL |
| 25 | atypical glycine encephalopathy | 98% | DL |
| 26 | chromosome 15q11.2 deletion syndrome | 98% | DL |
| 27 | 16q24.3 microdeletion syndrome | 98% | DL |
| 28 | occipital pachygyria and polymicrogyria | 98% | DL |
| 29 | Tourette syndrome | 98% | DL |
| 30 | autism (disease) | 97% | DL |
| 31 | epsilon-trimethyllysine hydroxylase deficiency | 97% | DL |
| 32 | hypotonia, infantile, with psychomotor retardation and characteristic facies | 97% | DL |
| 33 | childhood apraxia of speech | 97% | DL |
| 34 | anxiety disorder | 97% | DL |
| 35 | endogenous depression | 96% | DL |
| 36 | benign paroxysmal torticollis of infancy | 95% | DL |
| 37 | pyruvate carboxylase deficiency disease | 95% | DL |
| 38 | major depressive disorder | 94% | DL |
| 39 | agoraphobia | 94% | DL |
| 40 | striatal degeneration, autosomal dominant | 93% | DL |
| 41 | Ohdo syndrome and variants | 93% | DL |
| 42 | pervasive developmental disorder - not otherwise specified | 93% | DL |
| 43 | familial hypertryptophanemia | 93% | DL |
| 44 | dysthymic disorder | 92% | DL |
| 45 | phobic disorder | 92% | DL |
| 46 | blepharophimosis - intellectual disability syndrome, Ohdo type | 92% | DL |
| 47 | chromosome 2P16.3 deletion syndrome | 92% | DL |
| 48 | attention deficit-hyperactivity disorder | 91% | DL |
| 49 | melancholia | 91% | DL |
| 50 | neurotic depression | 91% | DL |
（上位50件を表示。全54件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。